glp-1 review article Glucagon-like peptide-1 receptor agonists and risk of gastrointestinal cancers: A systematic and meta-analysis of randomized controlled trials GLP-1_receptor_som_behandling_af_steatotisk_leversygdom - SDU

8-year trends in obesity, type 2 diabetes, and glucagon-like peptide-1 (GLP-1) use in patients with obstructive sleep apnea

Immunogenicity of exenatide may lead to the formation of anti-drug antibodies, reducing the medications efficacy and causing injection-site reactions (49)

Some individuals notice increased fatigue, muscle tightness, or reduced recovery when intake becomes lower over time

doi: 10.1007/s42000-018-0038-0 125 HunterKHolscherC

In a combination protocol, some researchers theorize that starting at a lower dose (1mg daily) and assessing tolerance before escalating to the full 2mg might reduce the risk of compounding side effects with retatrutide

Label your vial immediately after reconstitution